Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity: 2014-2024

Historic Liabilities and Shareholders Equity for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $294.8 million.

  • KalVista Pharmaceuticals' Liabilities and Shareholders Equity was N/A to $294.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $891.2 million, marking a year-over-year change of. This contributed to the annual value of $235.4 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Liabilities and Shareholders Equity is $294.8 million, which was up 83.31% from $160.8 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $294.8 million during Q4 2024, and its lowest value of $66.2 million during Q1 2021.
  • Over the past 2 years, KalVista Pharmaceuticals' median Liabilities and Shareholders Equity value was $160.8 million (recorded in 2024), while the average stood at $186.3 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first slumped by 35.68% in 2021, then climbed by 24.86% in 2024.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Liabilities and Shareholders Equity stood at $75.4 million in 2020, then tumbled by 35.68% to $66.2 million in 2021, then reached $138.7 million in 2023, then grew by 15.92% to $294.8 million in 2024.
  • Its Liabilities and Shareholders Equity was $294.8 million in Q4 2024, compared to $160.8 million in Q4 2024 and $200.2 million in Q3 2024.